MMEDF
Mind Medicine (MindMed) Inc. News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 2,
"returned": 2,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "7db574b4-5afa-47b1-a9b6-9d21a6c0dfb3",
"title": "MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York By Investing.com",
"description": "MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York",
"keywords": "",
"snippet": "-A single oral administration of MM120 100 µg met its primary and key secondary endpoints and maintained clinically and statistically significant HAM-A reducti...",
"url": "https://www.investing.com/news/press-releases/mindmed-presents-phase-2b-study-of-mm120-for-generalized-anxiety-disorder-gad-at-american-psychiatric-association-apa-annual-meeting-in-new-york-93CH-3419609",
"image_url": "https://i-invdn-com.investing.com/news/news_pile_69x52._800x533_L_1419494209.jpg",
"language": "en",
"published_at": "2024-05-04T12:12:03.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "MMEDF",
"name": "Mind Medicine (MindMed) Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 21.428757,
"sentiment_score": -0.2202,
"highlights": [
{
"highlight": "compared to placebo at 12 weeks with a 65% clinical response rate and a 48% clinical remission rate-\n\n-MindMed also presents two new epidemiology studies quantifying the burden of GAD in the US-\n\n-APA Annual Meeting, the largest psychiatric gathering in the world, is the first scientific presentation of MM120 Phase 2b data-\n\nNEW YORK--(BUSINESS WIRE)--<em>Mind</em>",
"sentiment": -0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Medicine</em> (<em>MindMed</em>) <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "f08a64f1-9d24-4890-9913-d42118cd12cf",
"title": "MindMed APA 2024: Screening Adults in the US General Population to Detect Cases of Undiagnosed Generalized Anxiety Disorder",
"description": "Screening Adults in the US General Population to Detect Cases of\n \n \n \n \n ...",
"keywords": "Markets",
"snippet": "Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is devel...",
"url": "https://www.marketscreener.com/quote/stock/MIND-MEDICINE-MINDMED-INC-120797784/news/MindMed-APA-2024-Screening-Adults-in-the-US-General-Population-to-Detect-Cases-of-Undiagnosed-Gener-46630825/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-05-04T12:03:08.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "MMEDF",
"name": "Mind Medicine (MindMed) Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 64.42567,
"sentiment_score": 0.6597,
"highlights": [
{
"highlight": "<em>Mind</em> <em>Medicine</em> (<em>MindMed</em>) <em>Inc</em>. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways.",
"sentiment": 0.6597,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "MMEDF",
"total_documents": 2,
"sentiment_avg": 0.21974998712539673
}
]
}
Other details
Exchange
- Over-the-counter Markets
- equity
- Healthcare
- us